The BET bromodomain inhibitor CPI203 improves lenalidomide activity in in vitro and in vivo models of multiple myeloma by synergistic blockade of Ikaros and c-Myc signaling. Homo sapiens
收藏NIAID Data Ecosystem2026-03-09 收录
下载链接：
https://www.ncbi.nlm.nih.gov/bioproject/PRJNA344666
下载链接
链接失效反馈官方服务：
资源简介：
Multiple myeloma (MM) cells were treated with the BET inhibitor CPI203 alone and in combination with lenalidomide plus dexamethasone in vitro and in vivo (mouse xenograft). We used microarrays to uncover the mechanisms underlying CPI-203 activity in MM, alone and in combination with lenalidomide plus dexamethasone (combo). Overall design: Global RNA expression was done in three MM cell lines treated in vitro with the BET inhibitor alone or with the combo for 6h.
创建时间：
2016-09-27
